

# RESPIRI LIMITED

ASX ANNOUNCEMENT  
(ASX:RSH)

TUESDAY 30 MAY 2017



## RESPIRI & CHINA

Respiri confirms it has received a written, commercial-in-confidence draft proposal to establish a partnership vehicle to manufacture and market an updated AirSonea in China.

The foundation partner is well known to Respiri and has had a strong working relationship with us.

As foreshadowed, partnership arrangements are complex and the draft format enables parties to work through and negotiate the details of key elements.

The Chinese market presents a significant opportunity for Respiri as rapid economic growth and urbanisation continues to cause increased prevalence of asthma and other respiratory diseases. Asthma education and management control in China remains poor and it has the world's highest mortality rate from this chronic disease.

Of particular relevance to Respiri, China has approximately 100 million asthma sufferers including millions of children. It is the leading cause of children's hospitalisation and imposes a significant burden on families and the China health system.

Respiri delivers an innovative solution to address the unmet need of regular monitoring, the key to asthma control in children and parental peace of mind. It further provides health authorities with a valuable tool to assist in patient education.

Respiri management will be visiting Hong Kong and its Israel R&D subsidiary next week.

**Jenni Lightowers**  
Company Secretary

Ph: 1800 476 632

For personal use only

## **About Respiri Limited**

Respiri Limited (ASX:RSH) is a medical technology company leading the way in the development of innovative devices and mobile health apps to improve the management of chronic and costly respiratory disorders such as asthma and COPD. Building on decades of experience in the research and development of cutting-edge clinical products for hospitals, the company has first-mover advantage in providing broad access to its proprietary acoustic based clinical solutions for remote monitoring with the development of a suite of over-the-counter connected devices. Health authorities universally agree that mHealth solutions can transform asthma care and health conscious consumers are rapidly embracing patient self-management with the aid of smartphones, the growth engine for Respiri's flagship product, AirSonea®. With the addition of new products, including a connected device for nocturnal monitoring in development, Respiri has a captive market, globally, of parents and carers of young children who cannot perform lung function tests. Respiri products have been cleared for use by the US Food and Drug Administration, the European Union CE, the Australian TGA and the commencement of an approval process for Asian markets has begun.

For personal use only